Emerging biopharma companies preparing for a first rare disease launch must balance speed, capital constraints and regulatory uncertainty while building the capabilities required for commercial success. This POV examines five critical launch success factors, including pre-launch preparation, governance, integrated infrastructure, organizational alignment and coordinated execution. Through a real-world launch example, readers will learn how an integrated partnership model can accelerate readiness, reduce operational complexity, preserve strategic control and support patient access from day one.
FDA grants accelerated approval to INOVIO’s Voceryq to reduce surgical burden in recurrent respiratory papillomatosis, Brox.AI’s Hamish Brocklebank on the three levels of digital clone use cases in pharma, and CytoDyn’s Dr. Jay Lalezari on his path from HIV clinician to CEO.
PhRMA's Scott LaGanga discusses the expanding influence of state policymaking on drug pricing, PBM reform, and efforts to translate policy changes into lower out-of-pocket costs for patients.
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
